Cumberland Pharmaceuticals Hits New 52-Week High of $6.90

Cumberland Pharmaceuticals, Inc. has reached a significant milestone by hitting a new 52-week high of USD 6.90 on June 29, 2026. This achievement marks a remarkable increase in the company's stock price, reflecting a 381.69% performance over the past year, significantly outpacing the S&P 500's 20.53% gain during the same period. As a microcap company in the Pharmaceuticals & Biotechnology industry, Cumberland Pharmaceuticals has a market capitalization of USD 46 million. Despite its recent stock performance, the company remains in a loss-making position, with a negative return on equity of -11.00%. The stock's price-to-book ratio stands at 1.85, indicating its valuation relative to its net assets. Cumberland Pharmaceuticals has not declared any dividends, and its debt-to-equity ratio is reported at -0.23, suggesting a unique financial structure. The stock's previous 52-week low was recorded at USD 1.85, highlighting the significant upward movement in its price. This milestone reflects the company's evolving market position within the competitive pharmaceuticals landscape.